Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens
Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved..
BACKGROUND: Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen.
PATIENTS AND METHODS: 267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant.
RESULTS: 41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001).
CONCLUSION: Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Anticancer research - 35(2015), 1 vom: 13. Jan., Seite 379-83 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fujii, Takeo [VerfasserIn] |
|---|
| Themen: |
6L8OF9XRDC |
|---|
| Anmerkungen: |
Date Completed 10.03.2015 Date Revised 21.03.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM244981493 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM244981493 | ||
| 003 | DE-627 | ||
| 005 | 20231224135855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0816.xml |
| 035 | |a (DE-627)NLM244981493 | ||
| 035 | |a (NLM)25550575 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fujii, Takeo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2015 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. | ||
| 520 | |a BACKGROUND: Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen | ||
| 520 | |a PATIENTS AND METHODS: 267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant | ||
| 520 | |a RESULTS: 41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001) | ||
| 520 | |a CONCLUSION: Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fosaprepitant | |
| 650 | 4 | |a anthracycline | |
| 650 | 4 | |a cisplatin | |
| 650 | 4 | |a infusion site adverse events | |
| 650 | 7 | |a Anthracyclines |2 NLM | |
| 650 | 7 | |a Antiemetics |2 NLM | |
| 650 | 7 | |a Morpholines |2 NLM | |
| 650 | 7 | |a fosaprepitant |2 NLM | |
| 650 | 7 | |a 6L8OF9XRDC |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Nishimura, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Urayama, Kevin Y |e verfasserin |4 aut | |
| 700 | 1 | |a Kanai, Hisako |e verfasserin |4 aut | |
| 700 | 1 | |a Ishimaru, Hiromasa |e verfasserin |4 aut | |
| 700 | 1 | |a Kawano, Junko |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamauchi, Hideko |e verfasserin |4 aut | |
| 700 | 1 | |a Yamauchi, Teruo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 35(2015), 1 vom: 13. Jan., Seite 379-83 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2015 |g number:1 |g day:13 |g month:01 |g pages:379-83 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2015 |e 1 |b 13 |c 01 |h 379-83 | ||